Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Intellia Therapeutics, Inc. (NTLA)
|
Add to portfolio |
|
|
|
| Price: |
$118.99
| | Metrics |
| OS: |
88.5
|
M
| |
-37
|
% ROE
|
| Market cap: |
$10.5
|
B
| |
-46
|
% ROIC
|
|
Net cash:
|
$172
|
M
| |
$1.94
|
per share
|
|
EV:
|
$10.4
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($496)
|
M
| |
|
|
| EPS |
($5.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 52.1 | 420.0 | 33.1 | 229.8 | 58.0 | 150.4 | 43.1 | 30.4 |
| Revenue growth | 57.7% | 82.8% | -43.0% | 52.8% | 34.5% | | 41.6% | 16.5% |
| Cost of goods sold | 454.3 | 510.3 | 300.9 | 300.9 | 194.6 | 242.8 | 149.5 | 0.0 |
| Gross profit | -402.2 | -90.3 | -267.9 | -71.1 | -136.6 | -92.4 | -106.4 | 30.4 |
| Gross margin | -771.6% | -21.5% | -810.4% | -30.9% | -235.5% | -61.4% | -246.8% | 100.0% |
| Selling, general and administrative | 56.0 | | 0.0 | | 0.0 | | 0.0 | |
| Research and development | | | | | | | | 89.1 |
| General and administrative | | 90.3 | 0.0 | 71.1 | 0.0 | 44.2 | 0.0 | 32.2 |
| EBIT | -402.2 | -482.7 | -267.9 | -269.2 | -136.6 | -136.6 | -106.4 | -90.9 |
| EBIT margin | -771.6% | -114.9% | -810.4% | -117.1% | -235.5% | -90.8% | -246.8% | -298.6% |
| Pre-tax income | -474.2 | -474.2 | -267.9 | -267.9 | -134.2 | -134.2 | -99.5 | -85.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -474.2 | -474.2 | -267.9 | -267.9 | -134.2 | -134.2 | -99.5 | -85.3 |
| Net margin | -909.8% | -112.9% | -810.5% | -116.6% | -231.5% | -89.2% | -230.9% | -280.4% |
| |
| Diluted EPS | ($6.16) | ($6.16) | ($3.78) | ($3.78) | ($2.40) | ($2.40) | ($2.11) | ($1.98) |
| Shares outstanding (diluted) | 77.0 | 77.0 | 70.9 | 70.9 | 56.0 | 56.0 | 47.2 | 43.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|